Results 141 to 150 of about 7,192,603 (344)

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

open access: yesMolecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker   +16 more
wiley   +1 more source

Efficient Graphene Production by Combined Bipolar Electrochemical Intercalation and High-Shear Exfoliation

open access: yesACS Omega, 2017
Emil Tveden Bjerglund   +5 more
doaj   +1 more source

Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors [PDF]

open access: gold, 2019
Rani K. Powers   +20 more
openalex   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad   +17 more
wiley   +1 more source

Human SREBP1c Expression in Liver Is Directly Regulated by Peroxisome Proliferator-activated Receptor α (PPARα) [PDF]

open access: hybrid, 2011
Ana Julia Fernández-Álvarez   +5 more
openalex   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

open access: yesMolecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande   +11 more
wiley   +1 more source

Nrf2 Activator PB125® as a Potential Therapeutic Agent against COVID-19 [PDF]

open access: gold, 2020
Joe M. McCord   +4 more
openalex   +1 more source

Ovary transplantation: to activate or not to activate [PDF]

open access: yesHuman Reproduction, 2015
Kazuhiro, Kawamura   +7 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy